HIV VACCINE DESIGN AND DEVELOPMENT TEAMS (HVD

HIV 疫苗设计和开发团队 (HVD

• 批准号: 8930878
• 负责人: CHARLES NICOLETTE
• 金额: $ 50.51万
• 依托单位: ARGOS THERAPEUTICS, INC.
• 依托单位国家: 美国
• 财政年份: 2006
• 资助国家: 美国
• 起止时间: 2006-09-30 至 2016-07-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8930878
• 关键词: Autologous; CD4 Positive T Lymphocytes; CD8B1 gene; Cells; Dendritic Cells; Goals; HIV; HIV vaccine; Immune; Immune response; Immunotherapy; Measures; Memory; Molecular; Patients; Proteins; Research; T cell response; T-Lymphocyte; Testing; Therapeutic; design; in vitro Assay; monocyte; programs; response; vaccine development

The goal of this Research Program is to design, develop, and clinically test an autologous HIV immunotherapy capable of eliciting therapeutic immune responses and which is comprised of autologous monocyte-derived dendritic cells modified to express selected autologous HIV proteins representing a multiplicity of patient-specific quasispecies

本研究计划的目标是设计、开发和临床测试能够引发治疗性免疫应答的自体HIV免疫疗法，该疗法由自体单核细胞衍生的树突状细胞组成，该树突状细胞经修饰以表达代表多种患者特异性准种的选定自体HIV蛋白